JP2007522200A5 - - Google Patents

Download PDF

Info

Publication number
JP2007522200A5
JP2007522200A5 JP2006552710A JP2006552710A JP2007522200A5 JP 2007522200 A5 JP2007522200 A5 JP 2007522200A5 JP 2006552710 A JP2006552710 A JP 2006552710A JP 2006552710 A JP2006552710 A JP 2006552710A JP 2007522200 A5 JP2007522200 A5 JP 2007522200A5
Authority
JP
Japan
Prior art keywords
alkyl
methyl
ethyl
dimethyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006552710A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007522200A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2005/000251 external-priority patent/WO2005079807A1/en
Publication of JP2007522200A publication Critical patent/JP2007522200A/ja
Publication of JP2007522200A5 publication Critical patent/JP2007522200A5/ja
Pending legal-status Critical Current

Links

JP2006552710A 2004-02-13 2005-02-01 非定型抗精神病薬とコルチコトロピン放出因子拮抗薬の治療的組合せ Pending JP2007522200A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54473104P 2004-02-13 2004-02-13
PCT/IB2005/000251 WO2005079807A1 (en) 2004-02-13 2005-02-01 Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists

Publications (2)

Publication Number Publication Date
JP2007522200A JP2007522200A (ja) 2007-08-09
JP2007522200A5 true JP2007522200A5 (https=) 2008-03-21

Family

ID=34886075

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006552710A Pending JP2007522200A (ja) 2004-02-13 2005-02-01 非定型抗精神病薬とコルチコトロピン放出因子拮抗薬の治療的組合せ

Country Status (14)

Country Link
US (1) US20050209250A1 (https=)
EP (1) EP1718311A1 (https=)
JP (1) JP2007522200A (https=)
KR (1) KR20060110006A (https=)
CN (1) CN1917882A (https=)
AU (1) AU2005215257A1 (https=)
BR (1) BRPI0507609A (https=)
CA (1) CA2556160A1 (https=)
IL (1) IL177433A0 (https=)
NO (1) NO20064054L (https=)
RU (1) RU2006129307A (https=)
TW (1) TW200538128A (https=)
WO (1) WO2005079807A1 (https=)
ZA (1) ZA200606636B (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
EP2170399A1 (en) * 2007-06-05 2010-04-07 Synthon B.V. Intranasal administration of asenapine and pharmaceutical compositions therefor
AU2008337286B2 (en) * 2007-12-19 2014-08-07 Cancer Research Technology Limited Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
US20100298397A1 (en) * 2009-05-19 2010-11-25 Singh Nikhilesh N Method of treatment of obsessive compulsive disorder with ondansetron
CA2937222C (en) 2009-06-25 2019-06-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
LT2445502T (lt) 2009-06-25 2017-09-25 Alkermes Pharma Ireland Limited Heterocikliniai junginiai, skirti neurologinių ir fiziologinių susirgimų gydymui
WO2011084849A1 (en) * 2010-01-07 2011-07-14 Alkermes, Inc. Diaryldiazepine prodrugs for the treatment of neurological and psychological disorders
WO2011084846A1 (en) 2010-01-07 2011-07-14 Alkermes, Inc. Quaternary ammonium salt prodrugs
WO2011084848A2 (en) 2010-01-07 2011-07-14 Alkermes, Inc. Prodrugs of heteraromatic compounds
AU2011270701B2 (en) 2010-06-24 2015-05-14 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US20120302616A1 (en) * 2010-12-03 2012-11-29 Nikhilesh Singh Method of treatment of obsessive compulsive disorder with ondansetron
BR112013023847B1 (pt) 2011-03-18 2021-02-23 Alkermes Pharma Ireland Limited composições farmacêuticas compreendendo ésteres de sorbitano e uso das mesmas
NZ722096A (en) 2011-12-15 2016-11-25 Alkermes Pharma Ireland Ltd Prodrugs of secondary amine compounds
AU2013235526B2 (en) 2012-03-19 2017-11-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
AU2013235523B9 (en) 2012-03-19 2018-01-04 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
CA2867121C (en) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
JP6654042B2 (ja) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド 貯蔵安定性が改善された医薬組成物
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2015112642A1 (en) 2014-01-21 2015-07-30 Neurocrine Biosciences, Inc. Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
CN106132415A (zh) 2014-03-20 2016-11-16 奥克梅斯制药爱尔兰有限公司 具有增加的注射速度的阿立哌唑制剂
EP3510029B1 (en) * 2016-09-07 2025-11-05 The Regents of The University of California Allosteric corticotropin-releasing factor receptor 1 (crfr1) antagonists that decrease p-tau and improve cognition
WO2018115010A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
ES2769286T3 (es) 2016-12-20 2020-06-25 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina
ES2881783T3 (es) 2017-06-26 2021-11-30 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona
WO2019032720A1 (en) 2017-08-09 2019-02-14 Sanford Burnham Prebys Medical Discovery Institute APELIN RECEPTOR AGONISTS AND METHODS OF USE
CN118845788A (zh) 2017-08-14 2024-10-29 云杉生物科学公司 促肾上腺皮质激素释放因子受体拮抗剂
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
EP4438124A3 (en) 2018-04-27 2024-12-18 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
CA3101420A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CA3121920A1 (en) 2018-12-07 2020-06-11 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
JP7623365B2 (ja) 2019-09-27 2025-01-28 ニューロクライン バイオサイエンシーズ,インコーポレイテッド Crf受容体アンタゴニストおよび使用方法
BR112023002497A2 (pt) 2020-08-12 2023-05-02 Spruce Biosciences Inc Métodos e composições para tratamento da síndrome dos ovários policísticos
WO2022173333A2 (en) * 2021-02-10 2022-08-18 Gero Pte. Ltd. Compounds, compositions and methods for treating age-related diseases and conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
TW530047B (en) * 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
TW477787B (en) * 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
EP1040831A3 (en) * 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
US6432989B1 (en) * 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders

Similar Documents

Publication Publication Date Title
JP2007522200A5 (https=)
RU2006129307A (ru) Терапевтические комбинации атипичных нейролептиков с антагонистами кортикотропин-рилизинг фактора
AU776077B2 (en) Use of CRF antagonists and related compositions
RU2221799C2 (ru) Антагонисты кортикотропин-рилизинг фактора
EP1149583A2 (en) Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
JP2022184886A5 (https=)
AU776724B2 (en) Use of corticotropin releasing factor antagonists and related compositions
JP2018529731A5 (https=)
JP2020504136A5 (https=)
RU2007134899A (ru) ПРОИЗВОДНЫЕ АЦЕТИЛЕНИЛ-ПИРАЗОЛО-ПИРИМИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGLuR2
RU97100192A (ru) Антагонисты кортикотропин-рилизинг фактора
JP2016537384A5 (https=)
JP2005500315A5 (https=)
JP2017515848A5 (https=)
JP2007523151A5 (https=)
JP2004527560A5 (https=)
RU2007107910A (ru) Гетероциклические соединения
AU2263400A (en) QT dispersion and heart rate variability improvement with CRF antagonists to prevent sudden death
JP2013500247A5 (https=)
JP2019536768A5 (https=)
JP2019503337A5 (https=)
RU2014151004A (ru) Пирролопиримидоновые и пирролопиридоновые ингибиторы танкиразы
RU2009123930A (ru) Химические соединения 637: пиридопиримидиндионы в качестве ингибиторов pde4
RU2014126750A (ru) Ингибиторы тирозинкиназы брутона
RU2019108259A (ru) Комбинированная терапия для лечения гепатоцеллюлярной карциномы